塔拉妥单抗在经治小细胞肺癌患者中的群体药代动力学
本研究基于420例经治小细胞肺癌患者的8509份样本,建立塔拉妥单抗的群体药代动力学模型。结果显示二室模型线性消除可良好描述其药代特征,清除率为0.649 L/天,中央分布容积3.44 L,终末半衰期11.2天,年龄、性别、体重、种族、肝肾功能等协变量均未导致临床有意义的暴露差异,无需据此调整剂量。
要点
- 塔拉妥单抗药代动力学呈二室模型线性消除,典型73 kg个体清除率0.649 L/天、中央分布容积3.44 L。
- 模型估计终末消除半衰期中位数为11.2天。
- 年龄、性别、体重、种族、肝肾功能、既往治疗线数、基线疾病状态及抗药抗体出现均未导致临床有意义的暴露差异,无需剂量调整。
核心结论
- 塔拉妥单抗药代动力学可用二室模型线性消除良好描述,评估的内在和外在协变量均未导致临床有意义的暴露差异,无需基于这些协变量调整剂量。
研究设计与样本
- 基于420例经治小细胞肺癌患者的8509份样本,汇总1期DeLLphi-300研究(0.003–100 mg每2周及200 mg每3周)和2期DeLLphi-301研究(10 mg和100 mg每2周)数据。
- 采用NONMEM(v7.5)非线性混合效应建模,并用标准统计方法验证,通过模拟评估协变量影响。
主要发现
- 典型73 kg个体清除率为0.649 L/天,中央分布容积为3.44 L,模型估计终末消除半衰期中位数为11.2天。
- 药代动力学不受年龄、性别、种族、民族、肝肾功能估计、既往治疗线数或基线疾病状态影响。
- 研究期间任何时间出现抗药抗体和体重是清除率的显著协变量,亚洲种族和体重是中央分布容积的显著协变量,但未导致临床有意义的暴露影响。
临床怎么用
- 基于年龄、性别、体重、种族、民族、肝肾功能、既往治疗线数、基线疾病状态及抗药抗体出现,均无需调整塔拉妥单抗剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Tarlatamab is a first in class, half-life extended delta-like ligand 3 (DLL3) directed bispecific T-cell engager (BiTE®) immunotherapy that has shown durable efficacy in patients with previously treated small cell lung cancer (SCLC). The purpose of this analysis was to develop a population pharmacokinetic (PK) model for tarlatamab. METHODS: This analysis includes data from 420 patients with previously treated small cell lung cancer (8509 samples) pooled across the Phase 1 DeLLphi-300 study (dose range 0.003-100 mg every 2 weeks and 200 mg every 3 weeks) and Phase 2 DeLLphi-301 study (10 mg and 100 mg every 2 weeks). The data were analyzed using a nonlinear-mixed effects modeling approach implemented in NONMEM (v7.5) software and validated using standard statistical approaches. The effects of intrinsic and extrinsic factors on PK parameters and exposures of tarlatamab were evaluated, and the impact of identified covariates were further assessed using simulations. RESULTS: Tarlatamab serum concentration data were best described by a two-compartment model with linear elimination. Tarlatamab clearance (CL) and central volume of distribution (VC) were 0.649 L/day and 3.44 L, respectively, for a typical 73-kg individual. The model-estimated median terminal phase elimination half-life was 11.2 days. Tarlatamab pharmacokinetics were not impacted by age, sex, ethnicity, estimates of renal and hepatic function, prior lines of therapy, or baseline disease status. The presence of antidrug antibody (ADA) at any time during the study and bodyweight were found to be statistically significant covariates on CL, and Asian race and bodyweight were found to be statistically significant covariates on VC; however, they did not lead to a clinically meaningful impact on exposures. CONCLUSIONS: The pharmacokinetics of tarlatamab was well-described by a two-compartment model with linear elimination. No clinically significant differences were observed on the basis of age, sex, bodyweight, race, ethnicity, estimates of renal and hepatic function, prior lines of therapy, baseline disease status, or emergence of ADA. These results support that no dose adjustment is required on the basis of any of the evaluated covariates.
引用
- Kong S, Minocha M, Chen PW, et al. Population Pharmacokinetics of Tarlatamab, a Half-Life Extended DLL3-Directed Bispecific T-Cell Engager in Patients with Previously Treated Small Cell Lung Cancer. Clin Pharmacokinet. 2025. PMID: 40261494. doi:10.1007/s40262-025-01499-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。